Author: Emig, Christopher J.; Mena, Marco A.; Henry, Steven J.; Vitug, Adela; Ventura, Christian John; Fox, Douglas; Nguyenla, Xammy Huu; Xu, Haiyue; Moon, Chaeho; Sahakijjpijarn, Sawittree; Kuehl, Philip J.; Revelli, David; Cui, Zengrong; Williams, Robert O.; Christensen, Dale J.
Title: AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo Cord-id: oelpnf4u Document date: 2021_10_13
ID: oelpnf4u
Snippet: Infections from the SARS-CoV-2 virus have killed over 4.6 million people since it began spreading through human populations in late 2019. In order to develop a therapeutic or prophylactic antibody to help mitigate the effects of the pandemic, a human monoclonal antibody (mAb) that binds to the SARS-CoV-2 spike protein was isolated from a convalescent patient following recovery from COVID-19 disease. This mAb, designated AUG-3387, demonstrates a high affinity for the spike protein of the original
Document: Infections from the SARS-CoV-2 virus have killed over 4.6 million people since it began spreading through human populations in late 2019. In order to develop a therapeutic or prophylactic antibody to help mitigate the effects of the pandemic, a human monoclonal antibody (mAb) that binds to the SARS-CoV-2 spike protein was isolated from a convalescent patient following recovery from COVID-19 disease. This mAb, designated AUG-3387, demonstrates a high affinity for the spike protein of the original viral strains and all variants tested to date. In vitro pseudovirus neutralization and SARS-CoV-2 neutralization activity has been demonstrated in vitro. In addition, a dry powder formulation has been prepared using a Thin-Film Freezing (TFF) process that exhibited a fine particle fraction (FPF) of 50.95 ± 7.69% and a mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of 3.74 ± 0.73 µm and 2.73 ± 0.20, respectively. The dry powder is suitable for delivery directly to the lungs of infected patients using a dry powder inhaler device. Importantly, AUG-3387, administered as a liquid by intraperitoneal injection or the dry powder formulation delivered intratracheally into Syrian hamsters 24 hours after intranasal SARS-CoV-2 infection, demonstrated a dose-dependent reduction in the lung viral load of the virus. These data suggest that AUG-3387 formulated as a dry powder demonstrates potential to treat COVID-19.
Search related documents:
Co phrase search for related documents- absence presence and adequate care: 1
- absence presence and load reduction: 1, 2
- absence presence and local delivery: 1
- absence presence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- absence presence and lung function: 1, 2
- absence presence and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8
- active viral load and lung tissue: 1
- additional benefit and low disease burden: 1
- additional benefit and lung function: 1
- adequate care and load reduction: 1
- adequate care and low disease burden: 1
- adequate care and lung disease: 1
- adequate care and lung function: 1
- adequate care and lung tissue: 1
- administration demonstrate and lung tissue: 1, 2
- load reduction and lung disease: 1
- load reduction and lung function: 1
- load reduction and lung tissue: 1, 2, 3, 4
- load reduction and lung tissue load reduction: 1
Co phrase search for related documents, hyperlinks ordered by date